HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained a Buy rating for Vir Biotechnology (NASDAQ:VIR) but lowered its price target from $95.00 to $85.00. Despite the reduction, the new target suggests a significant upside of 770.9% from the current price of $9.76. Vir Biotechnology is a commercial-stage immunology company with a focus on infectious diseases and has multiple technology platforms and product candidates.
January 23, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Vir Biotechnology with a reduced price target of $85, indicating a potential 770.9% increase from the current price.
The maintenance of a Buy rating combined with a substantial potential upside based on the new price target could generate positive investor sentiment and drive short-term interest in VIR shares. However, the confidence is not at the maximum due to the inherent unpredictability of market reactions to analyst ratings and price target adjustments.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100